Boston Tech
Moderna Put CAR-T in a Vial, and Cambridge Called It a Platform
Cambridge-based Moderna unveiled mRNA-6007, an in vivo CAR-T bet on lupus and related autoimmune disease that could make cell therapy less bespoke.
Boston Tech
Boston Dynamics Is Building a Bigger Waltham Robot Lair
Boston Dynamics will invest $100 million in a new Waltham robotics and AI center, adding 1,250 jobs by 2033 in a serious Massachusetts flex.
Boston Tech
MIT Built a 6 Milliwatt Robot Chip Because Boston Thinks HVAC Ducts Need Homework
MIT's new Gleanmer chip maps 3D space for tiny robots at under 6 milliwatts, giving Boston robotics another deeply practical flex.
Boston Tech
Massachusetts AI Coalition Is Building a Winning AI Flywheel in Public
A positive check-in on the Massachusetts AI Coalition, Ryan Durkin's organizing work at WHOOP, and Boston's AI momentum.
Boston Tech
AbbVie Bought Apogee for $10.9 Billion Because Waltham Made Eczema Dosing Less Annoying
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.
Boston Tech
HyperLight Raised $80 Million So AI Servers Can Stop Shouting Through Copper
HyperLight raised $80 million on June 18 to scale Cambridge-built photonics for AI infrastructure, turning Boston optics into a real data-center bet.
Boston Tech
Spero Therapeutics Won FDA Approval for an Oral Carbapenem. Cambridge Just Sent the IV Pole Home.
Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.
Boston Tech
Foundation Alloy Raised $22 Million to Turn Boston Metallurgy Into an Industrial Flex
Foundation Alloy raised $22 million on June 16 to scale MIT-born solid-state metallurgy in Massachusetts with a new facility and Japan distribution.
Boston Tech
Akamai Built a Bouncer for AI Shopping Agents, Which Is Extremely Cambridge
Akamai's new agentic security framework aims to verify AI shopping agents at the edge, giving Cambridge a concrete, very Boston AI story.
Boston Tech
Agios Posted New Sickle Cell Data, and Cambridge Gets a Rare Clean Win
Agios unveiled detailed Phase 3 sickle cell data on June 13, 2026, giving Cambridge biotech a real win in a field where progress is hard to earn.
AI
Boston Needs a Foundation Model Champion. Liquid AI Is Ready.
Liquid AI could become Boston's pillar foundation-model company by building efficient AI for devices, vehicles, enterprises, and the physical world.
Boston Tech
Boston Tech Week Was Great, Weird, Exhausting, and Very Boston
Unfiltered Friday thoughts on the first Boston Tech Week: what worked, what got messy, and why Boston needs a nap before the weekend events.